Compare ASTRAZENECA PHARMA with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PFIZER - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PFIZER ASTRAZENECA PHARMA/
PFIZER
 
P/E (TTM) x 80.3 35.7 225.2% View Chart
P/BV x 24.3 6.1 398.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   PFIZER
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PFIZER
Mar-19
ASTRAZENECA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,2783,840 33.3%   
Low Rs8832,080 42.4%   
Sales per share (Unadj.) Rs228.4455.0 50.2%  
Earnings per share (Unadj.) Rs10.493.8 11.1%  
Cash flow per share (Unadj.) Rs16.3109.4 14.9%  
Dividends per share (Unadj.) Rs022.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8658.2 15.0%  
Shares outstanding (eoy) m25.0045.75 54.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.5 72.7%   
Avg P/E ratio x104.231.6 330.2%  
P/CF ratio (eoy) x66.427.1 245.5%  
Price / Book Value ratio x10.94.5 243.2%  
Dividend payout %024.0 0.0%   
Avg Mkt Cap Rs m27,008135,420 19.9%   
No. of employees `0001.42.6 51.5%   
Total wages/salary Rs m1,5353,238 47.4%   
Avg. sales/employee Rs Th4,210.97,911.4 53.2%   
Avg. wages/employee Rs Th1,132.21,230.9 92.0%   
Avg. net profit/employee Rs Th191.11,630.7 11.7%   
INCOME DATA
Net Sales Rs m5,71020,815 27.4%  
Other income Rs m1231,674 7.3%   
Total revenues Rs m5,83322,489 25.9%   
Gross profit Rs m4635,712 8.1%  
Depreciation Rs m147714 20.6%   
Interest Rs m073 0.0%   
Profit before tax Rs m4386,599 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1792,309 7.7%   
Profit after tax Rs m2594,291 6.0%  
Gross profit margin %8.127.4 29.5%  
Effective tax rate %40.835.0 116.8%   
Net profit margin %4.520.6 22.0%  
BALANCE SHEET DATA
Current assets Rs m3,20927,167 11.8%   
Current liabilities Rs m2,0708,917 23.2%   
Net working cap to sales %20.087.7 22.8%  
Current ratio x1.63.0 50.9%  
Inventory Days Days7268 106.7%  
Debtors Days Days3530 116.0%  
Net fixed assets Rs m7908,862 8.9%   
Share capital Rs m50458 10.9%   
"Free" reserves Rs m2,41929,656 8.2%   
Net worth Rs m2,46930,113 8.2%   
Long term debt Rs m025 0.0%   
Total assets Rs m4,60539,400 11.7%  
Interest coverage xNM91.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.5 234.7%   
Return on assets %5.611.1 50.8%  
Return on equity %10.514.2 73.6%  
Return on capital %17.722.1 80.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300428 69.9%   
Fx outflow Rs m2,015786 256.2%   
Net fx Rs m-1,715-358 479.0%   
CASH FLOW
From Operations Rs m88978 9.0%  
From Investments Rs m-94351 -26.7%  
From Financial Activity Rs mNA-1,099 0.0%  
Net Cashflow Rs m-6231 -2.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 4.9 320.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.7 38.4%  
Shareholders   12,856 85,207 15.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 674 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day and ended lower. Investors were worried about the economic impact and uncertainty over the coronavirus pandemic.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

One Stock that is All Charged Up for the Post Coronavirus Rebound(The 5 Minute Wrapup)

Apr 1, 2020

A stock with strong moat is currently trading near 5-year lows.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 3, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS